DTIL - Precision BioSciences

-

$undefined

N/A

(N/A)

Precision BioSciences NasdaqCM:DTIL Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Location: 302 East Pettigrew St., Durham, NC, 27701, United States | Website: https://precisionbiosciences.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

7.38%

Insider Ownership

10.57%

Institutional Own.

43.39%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details
Cancer, B-cell lymphoma, Diffuse large B cell lymphoma

Phase 1/2

Data readout

ECUR-506 Details
Ornithine transcarbmylase deficiency

Phase 1/2

Data readout

PBGENE-HBV Details
Chronic hepatitis B, Viral infection, Liver disease

Phase 1

Data readout

PBCAR19B (CD19 Allogeneic CAR-T) Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 1

Update

PBCAR20A (targeting CD20) Details
Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia

Failed

Discontinued

PBCAR269A (BCMA) Details
Cancer, Multiple myeloma

Failed

Discontinued